Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canvuparatide in Adult Patients With Hypoparathyroidism
NCT07699471Phase 3Recruiting
- Sponsor
- MBX Biosciences, Inc.
- Start
- Aug 2026
- Primary completion
- Jan 2028
- Countries
- 2
01
Overview
A Phase 3 trial of canvuparatide in hypoparathyroidism, sponsored by MBX Biosciences, Inc.. Started Aug 2026; status: recruiting.
02
Drugs
canvuparatide
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT07699471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07699471.